Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.64 |
| ▸ | OGFRL1 | Q5TC84 | 12/20 | 0.64 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cebranopadol SCHEMBL154336 | 0.78 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL566256 | 0.78 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL29353179 | 0.78 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL10035739 | 0.78 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL1703335 | 0.78 | OPRM1 (0.56) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL18452424 | 0.78 | OPRM1 (0.65) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL3561227 | 0.78 | OPRM1 (0.58) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Lexanopadol SCHEMBL29930643 | 0.78 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Lexanopadol SCHEMBL381022 | 0.78 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL15007659 | 0.78 | OPRM1 (0.98) | OPRM1OGFRL1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048553-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-02-25 | — | — | US | claimed |
| EP-2121691-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7960404-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20100048553-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048553-A1 | Spirocyclic Cyclohexane Compounds | PKD2, PKD1, RYR1 | OPRM1 65/4885OGFRL1 672/4885OPRL1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.